Endonovo Therapeutics, Inc. filed its 10-K on Apr 14, 2022 for the period ending Dec 31, 2021. In this report its auditor, Rose, Snyder & Jacobs, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.002 USD | +33.33% | -9.09% | -77.01% |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
1st Jan change | Capi. | |
---|---|---|
-77.01% | 524K | |
+5.24% | 109B | |
+11.13% | 105B | |
-0.38% | 22.25B | |
-11.94% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.17% | 16.85B | |
+3.38% | 13.76B | |
+36.09% | 12.46B |
- Stock Market
- Equities
- ENDV Stock
- News Endonovo Therapeutics, Inc.
- Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt